Author:
Hong A. R.,Kim J. H.,Lee K. H.,Kim T. Y.,Im S. A.,Kim T. Y.,Moon H. G.,Han W. S.,Noh D. Y.,Kim S. W.,Shin C. S.
Funder
Seoul National University Hospital
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism
Reference37 articles.
1. Bauer M, Bryce J, Hadji P (2012) Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. Breast cancer (Dove Medical Press) 4:91–101
2. Hadji P (2010) Guidelines for Osteoprotection in breast cancer patients on an aromatase inhibitor. Breast care (Basel) 5:290–296
3. Becker T, Lipscombe L, Narod S, Simmons C, Anderson GM, Rochon PA (2012) Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer. J Am Geriatr Soc 60:1761–1767
4. Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, Cardoso F (2013) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi7–v23
5. Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69:73–82
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献